OBJECTIVE: The goal of this study was to assess the efficacy and tolerability of lis-dexamfetamine dimesylate (LDX) as an adjunct to nicotine replacement therapy in adult smokers with ADHD who were undergoing a quit attempt. METHODS:Thirty-two regular adult smokers with ADHD were randomized to receive LDX (n = 17) or placebo (n = 15) in addition to nicotine patch concurrent with a quit attempt. RESULTS: There were no differences between smokers assigned to LDX versus placebo in any smoking outcomes. Participants treated with LDX demonstrated significant reductions in self-reported and clinician-rated ADHD symptoms. LDX was well tolerated in smokers attempting to quit. DISCUSSION: In general, LDX does not facilitate smoking cessation in adults with ADHD more than does placebo, though both groups significantly reduced smoking. LDX demonstrated efficacy for reducing ADHD symptoms in adult smokers engaging in a quit attempt.
RCT Entities:
OBJECTIVE: The goal of this study was to assess the efficacy and tolerability of lis-dexamfetamine dimesylate (LDX) as an adjunct to nicotine replacement therapy in adult smokers with ADHD who were undergoing a quit attempt. METHODS: Thirty-two regular adult smokers with ADHD were randomized to receive LDX (n = 17) or placebo (n = 15) in addition to nicotine patch concurrent with a quit attempt. RESULTS: There were no differences between smokers assigned to LDX versus placebo in any smoking outcomes. Participants treated with LDX demonstrated significant reductions in self-reported and clinician-rated ADHD symptoms. LDX was well tolerated in smokers attempting to quit. DISCUSSION: In general, LDX does not facilitate smoking cessation in adults with ADHD more than does placebo, though both groups significantly reduced smoking. LDX demonstrated efficacy for reducing ADHD symptoms in adult smokers engaging in a quit attempt.
Authors: Andrea R Vansickel; William W Stoops; Paul E A Glaser; Megan M Poole; Craig R Rush Journal: Psychopharmacology (Berl) Date: 2011-05-18 Impact factor: 4.530
Authors: Brooke S G Molina; Andrea L Howard; James M Swanson; Annamarie Stehli; John T Mitchell; Traci M Kennedy; Jeffery N Epstein; L Eugene Arnold; Lily Hechtman; Benedetto Vitiello; Betsy Hoza Journal: J Child Psychol Psychiatry Date: 2018-01-08 Impact factor: 8.982
Authors: Scott H Kollins; Erin Schoenfelder; Joseph S English; F Joseph McClernon; Rachel E Dew; Scott D Lane Journal: Exp Clin Psychopharmacol Date: 2013-10 Impact factor: 3.157
Authors: Scott H Kollins; Joseph S English; Michelle E Roley; Benjamin O'Brien; Justin Blair; Scott D Lane; F Joseph McClernon Journal: Psychopharmacology (Berl) Date: 2012-12-18 Impact factor: 4.530
Authors: Maggie M Sweitzer; Scott H Kollins; Rachel V Kozink; Matt Hallyburton; Joseph English; Merideth A Addicott; Jason A Oliver; F Joseph McClernon Journal: Neuropsychopharmacology Date: 2017-10-20 Impact factor: 7.853